News

Tolera Therapeutics, a biotechnology company, has received orphan drug status from the FDA for its initial lead candidate, TOL101, for prophylaxis of acute rejection of solid organ transplantation.

Phadia, an in vitro allergy diagnostics company, has received the FDA clearance for its ImmunoCAP Rapid, the first point-of-care test to assist in the diagnosis of allergy in

Netherlands-based biopharmaceutical company Kiadis Pharma has reported promising preliminary clinical data on Atir showing its potential in mismatched bone marrow transplantations. The clinical results from 19 end stage

Alimera Sciences, a biopharmaceutical company engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals, has reported that an independent Data Safety Monitoring Board has recommended the

Denmark-based pharmaceutical company H Lundbeck has reported that the Psychopharmacology Drug Advisory Committee appointed by the FDA voted unanimously that Serdolect is efficacious in the treatment of patients

Germany-based biopharmaceutical company Paion and Ergomed Clinical Research, a clinical development company, have reported encouraging data from the open-label Phase IIa study with the N-methyl-D-aspartic acid receptor antagonist

Medifocus, a Canada-based capital pool company, has reported positive clinical results from Phase II breast cancer treatment study that demonstrate significant efficacy when using the company’s proprietary focused

BioStar Pharmaceuticals, a developer and manufacturer of pharmaceutical and medical nutrient products, has reported a net income of $6.69m, or $0.22 per diluted share, for 2008, compared to

Genentech, a biotechnology company, has initiated a phased voluntary withdrawal of the psoriasis drug Raptiva from the US market. The company’s decision is based on the association of